Efficacy and adverse reaction management of oncolytic viral intervention combined with chemotherapy in patients with liver metastasis of gastrointestinal malignancy

Jie Zhang, Qianyun He, Dongliang Mao, Chen Wang, Lei Huang, Mei Wang, Jun ZhangFrontiers in Oncology 2023 · DOI

Abstract

Liver metastasis remains a significant challenge in treating colorectal and gastric cancers. This study, published in Frontiers in Oncology, investigates the efficacy and safety of intratumoral oncolytic virus (OV) injections combined with chemotherapy. Analyzing 47 patients, the researchers evaluated clinical outcomes and the impact of a structured nursing protocol on managing adverse reactions. Results showed a 74.5% disease control rate, with manageable side effects such as fever and pain. The study concludes that comprehensive nursing interventions are vital for the successful implementation of recombinant human adenovirus type 5 therapy in this patient population.

The Challenge of Liver Metastasis

Liver metastasis is the leading cause of mortality for patients with gastrointestinal malignancies, with 5-year survival rates often falling below 5%. While surgical resection is the gold standard, 80-90% of these metastases are unresectable at the time of diagnosis.

Oncolytic viruses (OVs)—engineered to selectively infect and lyse tumor cells while sparing healthy tissue—represent a promising frontier in biological therapy. However, the clinical implementation of OVs faces two major hurdles: the technical difficulty of direct intratumoral delivery and the management of the body’s inflammatory response to the virus. This paper addresses the gap in clinical management, proposing a systematic nursing framework to ensure treatment adherence and patient quality of life.

Methods and Procedural Framework

The study prospectively analyzed 47 patients at Ruijin Hospital (Shanghai) between June 2021 and October 2022. Patients received intratumoral injections of a recombinant human adenovirus type 5 (brand name: Ancore), with dosages titrated based on the longest diameter of the target liver lesion. This viral intervention was combined with either chemotherapy plus immunotherapy (23.4%) or chemotherapy plus targeted therapy (76.6%).

A core contribution of this work is the systematic nursing protocol utilized throughout the study. The authors employed an "Evaluation-Diagnosis-Planning-Implementation-Evaluation" model to manage the patient journey, including preoperative nutritional loading, psychological interventions, and rigorous postoperative monitoring of systemic inflammatory markers.

Figure 1: Flow diagram of the study process, detailing pre-operation, intraoperative, and postoperation stages.

Key Results and Clinical Efficacy

The intervention yielded a disease control rate (DCR) of 74.5% according to RECIST 1.1 criteria. Specifically, 5 patients (10.6%) achieved partial remission (PR), while 30 patients (63.8%) achieved stable disease (SD).

Figure 2: Postoperative liver MRI showing target organ response to oncolytic virus injection.

Safety was a primary focus of the analysis. No drug-related deaths occurred. The most frequent adverse effects were fever (78.7%), pain (57.4%), and bone marrow suppression (48.9%). Despite the invasive nature of the injections, 72% of patients maintained Child-Pugh Grade A liver function postoperatively, suggesting the treatment is relatively well-tolerated by the liver parenchyma.

Insights: Nursing as a Clinical Determinant

The authors argue that the efficacy of oncolytic virotherapy is inextricably linked to nursing care. Because OVs trigger a robust immune response, side effects like high fevers (up to 39°C) are common. Without proactive management, these adverse reactions could lead to patient distress and treatment discontinuation.

Furthermore, the study touches on the synergistic potential of OVs. By lysing tumor cells, the virus releases tumor-associated antigens, essentially turning "cold" (immunosuppressive) tumors "hot" and making them more susceptible to the accompanying chemotherapy and immunotherapy. Direct intratumoral injection remains the preferred delivery method to bypass the "neutralization barrier" of antibodies in the bloodstream.

Limitations and Future Work

The authors acknowledge several limitations, including a small sample size (n=47) from a single center and a relatively short 6-month follow-up period. Long-term Overall Survival (OS) data is still needed to determine if the observed stable disease translates into significant life extension. Future research should focus on larger, multi-center trials and the development of next-generation OVs that can better penetrate dense tumor stroma or resist systemic neutralization.

Summary updated

Abstract

Background The liver is a key target organ for colorectal and gastric cancer metastasis. One of the challenges in the treatment of colorectal and gastric cancers is the management of liver metastasis. This study aimed to investigate the efficacy, adverse effects, and coping strategies of oncolytic virus injection in patients with liver metastases of gastrointestinal malignancies. Methods We prospectively analyzed patients treated at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine from June 2021 to October 2022. 47 patients with gastrointestinal cancer liver metastasis were included in the study. The data, including clinical manifestations, imaging, tumor markers, postoperative adverse reactions, psychological intervention, dietary guidance, and adverse reaction management were evaluated. Results Oncolytic virus injection was successful in all patients, and no drug injection-related deaths occurred. The adverse effects, such as fever, pain, bone marrow suppression, nausea, and vomiting, were mild and resolved subsequently. Based on the comprehensive intervention of nursing procedures, the postoperative adverse reactions of patients were effectively alleviated and treated. None of the 47 patients had any puncture point infections, and the pain caused by the invasive operation was relieved quickly. After 2 courses of oncolytic virus injection, postoperative liver MRI showed 5 partial remissions, 30 stable diseases, and 12 progressive diseases in target organs. Conclusion Interventions based on nursing procedures can ensure the smooth treatment of recombinant human adenovirus type 5 in patients with liver metastases of gastrointestinal malignant tumors. This is of great importance for clinical treatment and significantly reduces patient complications and improves the patient’s quality of life.
BibTeX
@inproceedings{zhang2023efficacy,
  author = {Jie Zhang and Qianyun He and Dongliang Mao and Chen Wang and Lei Huang and Mei Wang and Jun Zhang},
  title = {{Efficacy and adverse reaction management of oncolytic viral intervention combined with chemotherapy in patients with liver metastasis of gastrointestinal malignancy}},
  booktitle = {Frontiers in Oncology},
  year = {2023},
  doi = {10.3389/fonc.2023.1159802},
}
Figure